Kronos Bio, Inc.

NasdaqGS:KRON 주식 보고서

시가총액: US$74.5m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Kronos Bio 관리

관리 기준 확인 3/4

Kronos Bio's CEO는 Norbert Bischofberger, Aug2018 에 임명되었습니다 의 임기는 5.83 년입니다. 총 연간 보상은 $ 1.76M, 32.9% 로 구성됩니다. 32.9% 급여 및 67.1% 보너스(회사 주식 및 옵션 포함). 는 $ 10.88M 가치에 해당하는 회사 주식의 17.93% 직접 소유합니다. 10.88M. 경영진과 이사회의 평균 재임 기간은 각각 2.3 년과 5 년입니다.

주요 정보

Norbert Bischofberger

최고 경영자

US$1.8m

총 보상

CEO 급여 비율32.9%
CEO 임기5.8yrs
CEO 소유권17.9%
경영진 평균 재임 기간2.3yrs
이사회 평균 재임 기간5yrs

최근 관리 업데이트

Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Jun 20
Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Recent updates

Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Jun 20
Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Jun 11
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Kronos Bio: Still Promising But Riskier Following ASCO Update

Jun 05

Kronos Bio: Underestimated Drug Discovery Platform

May 06

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

Jan 19
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate

Aug 21
We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate

We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully

Feb 22
We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Nov 01
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Kronos Bio, Invivoscribe to develop companion diagnostic for leukemia drug entospletinib

Aug 16

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

Jul 07
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely

Feb 01
We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely

How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?

Mar 03
How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?

Read This Before Selling Kronos Bio, Inc. (NASDAQ:KRON) Shares

Jan 09
Read This Before Selling Kronos Bio, Inc. (NASDAQ:KRON) Shares

Kronos Bio  EPS misses by $4.10

Nov 18

CEO 보상 분석

Norbert Bischofberger 의 보수는 Kronos Bio 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$116m

Dec 31 2023US$2mUS$580k

-US$113m

Sep 30 2023n/an/a

-US$119m

Jun 30 2023n/an/a

-US$120m

Mar 31 2023n/an/a

-US$123m

Dec 31 2022US$3mUS$580k

-US$133m

Sep 30 2022n/an/a

-US$164m

Jun 30 2022n/an/a

-US$165m

Mar 31 2022n/an/a

-US$161m

Dec 31 2021US$645kUS$320k

-US$151m

Sep 30 2021n/an/a

-US$122m

Jun 30 2021n/an/a

-US$128m

Mar 31 2021n/an/a

-US$108m

Dec 31 2020US$15mUS$399k

-US$88m

Sep 30 2020n/an/a

-US$61m

Jun 30 2020n/an/a

-US$25m

Mar 31 2020n/an/a

-US$20m

Dec 31 2019US$280kUS$200k

-US$16m

보상 대 시장: Norbert 의 총 보상 ($USD 1.76M )은 US 시장( $USD 683.56K ).

보상과 수익: Norbert 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Norbert Bischofberger (68 yo)

5.8yrs

테뉴어

US$1,761,537

보상

Dr. Norbert W. Bischofberger, Ph D., is Independent Director of Vir Biotechnology, Inc. from May 29, 2024. He has been an Independent Director of Morphic Holding, Inc. since June 14, 2019.Dr. Bischofberge...


리더십 팀

이름위치테뉴어보상소유권
Norbert Bischofberger
President5.8yrsUS$1.76m17.93%
$ 13.4m
Joshua Kazam
Co-Founder & Directorno dataUS$74.80k0.61%
$ 454.5k
David Tanen
Secretary & Directorno dataUS$74.80k1.52%
$ 1.1m
Deborah Knobelman
COO & CFOno data데이터 없음0.27%
$ 203.7k
Margaux Bennett
Vice President of Corporate Development & Investor Relations3.1yrs데이터 없음데이터 없음
Allison Frisbee
Senior Vice President of Corporate Operations & Legalless than a year데이터 없음0.34%
$ 253.6k
Charles Lin
Senior Vice President of Research & Development3.4yrs데이터 없음0.39%
$ 290.9k
Elizabeth Olek
Senior Vice President of Clinical Development2.3yrs데이터 없음0.32%
$ 239.7k
Wes Trotter
Senior Vice President of Drug Discovery & Pharmaceutical Development1.2yrs데이터 없음데이터 없음

2.3yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 관리: KRON 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Norbert Bischofberger
President6.2yrsUS$1.76m17.93%
$ 13.4m
Joshua Kazam
Co-Founder & Director7yrsUS$74.80k0.61%
$ 454.5k
David Tanen
Secretary & Director7yrsUS$74.80k1.52%
$ 1.1m
Owen Witte
Scientific Advisory Board Chairmanno data데이터 없음데이터 없음
Arie Belldegrun
Independent Chairman of the Board6.6yrsUS$117.20k1.13%
$ 842.7k
Elena Ridloff
Independent Director3.8yrsUS$89.17k0.042%
$ 31.4k
Taiyin Yang
Independent Director3.3yrsUS$88.70k0.019%
$ 14.1k
Roshawn Blunt
Independent Director2.6yrsUS$79.80k0%
$ 0
Angela Koehler
Scientific Advisory Board Memberno data데이터 없음데이터 없음
Robert Eisenman
Scientific Advisory Board Memberno data데이터 없음데이터 없음
Myles Brown
Scientific Advisory Board Memberno data데이터 없음데이터 없음
Katherine Stultz
Independent Director1.3yrsUS$105.68k0%
$ 0

5.0yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: KRON 의 이사회경험(평균 재직 기간 5 년)으로 간주됩니다.